Citation: Aj. Evans et Aj. Krentz, Insulin resistance and beta-cell dysfunction as therapeutic targets in type 2 diabetes, DIABET OB M, 3(4), 2001, pp. 219-229
Authors:
Dmitrewski, J
Krentz, AJ
Mayer, AD
Buckels, JAC
Barnes, AD
Smith, J
Nattrass, M
Citation: J. Dmitrewski et al., Metabolic and hormonal effects of tacrolimus (FK506) or cyclosporin immunosuppression following renal transplantation, DIABET OB M, 3(4), 2001, pp. 287-292
Citation: Aj. Krentz et al., Thiazolidinediones for type 2 diabetes - New agents reduce insulin resistance but need long term clinical trials, BR MED J, 321(7256), 2000, pp. 252-253
Citation: T. Sulkin et Aj. Krentz, Iatrogenic recurrent severe hypercalcaemia and renal impairment - Iatrogenic recurrent severe hypercalcaemia and renal impairment, POSTG MED J, 76(902), 2000, pp. 800
Citation: Aj. Krentz, Immunosuppression in renal transplantation - Postoperative glucose intolerance was almost certainly underestimated, BR MED J, 319(7217), 1999, pp. 1136-1137
Citation: A. Evans et Aj. Krentz, Benefits and risks of transfer from oral agents to insulin in type 2 diabetes mellitus, DRUG SAFETY, 21(1), 1999, pp. 7-22